NanoViricides, Inc. (NYSE American: NNVC) announced that President Dr. Anil R. Diwan was interviewed on the Mission Matters Podcast, where he discussed the company’s mission to revolutionize antiviral treatment through its nanoviricide platform and highlighted progress of lead drug candidate NV-387. During the interview, Dr. Diwan explained how nanoviricides are designed to prevent viral escape, function independently of patient immune status, and offer broad-spectrum potential across patient populations, from infants to geriatrics.
He noted that NV-387 has demonstrated efficacy against multiple unrelated viruses in lethal animal models, including Influenza, RSV, Coronaviruses, MPox, Smallpox, and Measles, and has completed a Phase I clinical trial with no reported adverse events. Dr. Diwan added that a Phase II clinical trial for NV-387 targeting MPox is ready to begin in the Democratic Republic of Congo following regulatory clearance, positioning the candidate as a potential empirical therapy for acute respiratory and other viral infections with an estimated market opportunity exceeding $17 billion by 2030.
To view the full press release, visit https://ibn.fm/EqHoV. The company’s lead drug candidate NV-387 is a broad-spectrum antiviral drug being developed as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPox/Smallpox infections. Another advanced candidate is NV-HHV-1 for the treatment of Shingles.
NanoViricides is a clinical stage company creating special purpose nanomaterials for antiviral therapy. Its novel nanoviricide class of drug candidates is based on intellectual property from TheraCour Pharma, Inc. The company holds a worldwide exclusive perpetual license to TheraCour nanomedicine technology for several drugs targeting specific human viral diseases, including HIV/AIDS, Hepatitis B and C, Rabies, Herpes, Influenza, Dengue, Ebola, and certain Coronaviruses.
The company notes that the path to drug development is lengthy and requires substantial capital, and there can be no assurance that any pharmaceutical candidates will show sufficient effectiveness and safety for human clinical development. For the latest news and updates, visit the company’s newsroom at https://ibn.fm/NNVC.
